Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.39 |
| ▸ | MGAT2 | Q10469 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31079070 | 0.79 | CYP19A1 (0.37) | AKR1B1 | |
| SCHEMBL31079010 | 0.79 | AKR1B1 (0.37) | MMP2MMP9MMP13AKR1B1AKR1A1 | |
| SCHEMBL14101183 | 0.78 | CYP2C9 (0.53) | MMP2MMP9AKR1B1KDM4E | |
| SCHEMBL11721916 | 0.75 | CYP2C9 (0.58) | LMNANPSR1SMN1; SMN2MMP2MMP9 | |
| SCHEMBL539101 | 0.73 | LMNA (0.74) | LMNANPSR1SMN1; SMN2MMP2MMP9 | |
| SCHEMBL1969070 | 0.72 | ADAM17 (0.49) | LMNANPSR1SMN1; SMN2MMP2MMP13 | |
| SCHEMBL1971074 | 0.71 | SMN1; SMN2 (0.50) | LMNANPSR1SMN1; SMN2MMP2MMP9 | |
| SCHEMBL542857 | 0.70 | TNF (0.50) | LMNANPSR1SMN1; SMN2MMP2MMP13 | |
| SCHEMBL10522876 | 0.70 | CYP2C9 (0.71) | LMNANPSR1SMN1; SMN2MMP2MMP9 | |
| SCHEMBL1970250 | 0.69 | MMP13 (0.51) | LMNANPSR1SMN1; SMN2MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168667-B2 | Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such | GALAPAGOS NV (BE) | 2012-05-01 | — | — | US | disclosed |
| EP-2026799-B1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | GALAPAGOS SAS (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-20100210699-A1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | DART THERAPUTICS, LLC. | 2010-08-19 | — | — | US | disclosed |
| US-20100063120-A1 | Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such | SASU, GALAPAGOS (FR) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210699-A1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | NR5A1, AR, HSD17B7 | TSHR 249/4885LMNA 4085/4885NPSR1 490/4885 |
| US-20100063120-A1 | Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such | NR5A1, AR, HSD17B7 | TSHR 253/4885LMNA 4071/4885NPSR1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.